We are live on
!
Find out more
SC
Sophrosyne Capital Portfolio holdings
AUM
$11.5M
1-Year Est. Return
17.82%
This Fund
S&P 500
This Quarter
Est. Return
+10.95%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$7K
(+0.01%)
Cap. Flow
-$8.9M
Cap. Flow
% of AUM
-7.79%
Top 10 Holdings %
Top 10 Hldgs %
52.99%
Holding
94
New
29
Increased
16
Reduced
28
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SYT
Syngenta Ag
SYT
|
+$5.86M |
| 2 |
BFYT
Benefytt Technologies, Inc. Class A Common Stock
BFYT
|
+$5.08M |
| 3 |
SHOR
ShoreTel, Inc.
SHOR
|
+$2.1M |
| 4 |
SANW
S&W Seed Co
SANW
|
+$1.65M |
| 5 |
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
|
+$1.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Calix
CALX
|
+$6.16M |
| 2 |
DRRX
DURECT Corp
DRRX
|
+$3.14M |
| 3 |
Lesaka Technologies
LSAK
|
+$3.03M |
| 4 |
Accuray
ARAY
|
+$2.56M |
| 5 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
+$2.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.71% |
| 2 | Technology | 20.22% |
| 3 | Communication Services | 8.22% |
| 4 | Materials | 7.79% |
| 5 | Financials | 5.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BEAT
1
DELISTED
BioTelemetry, Inc.
BEAT
| $11.1M | 9.71% |
1,098,174
-133,544
| -11% | -$1.23M |
|
|
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $7.61M | 6.66% |
388,004
-120,900
| -24% | -$2.36M |
|
3
Strategy Inc
MSTR
$54.6B
| $6.54M | 5.73% |
566,630
-30,000
| -5% | -$375K |
|
|
MEET
4
DELISTED
The Meet Group, Inc. Common Stock
MEET
| $6.29M | 5.51% |
1,930,135
-280,752
| -13% | -$751K |
|
|
SYT
5
DELISTED
Syngenta Ag
SYT
| $6.05M | 5.3% |
80,050
+78,700
| +5,830% | +$5.86M |
|
|
FLNA
6
Filana Therapeutics
FLNA
$44.6M
| $5.17M | 4.53% |
134,245
-46,472
| -26% | -$1.64M |
|
7
Arcturus Therapeutics
ARCT
$460M
| $4.96M | 4.34% |
39,037
-6,731
| -15% | -$998K |
|
|
BFYT
8
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $4.65M | 4.07% |
+449,845
| New | +$5.08M |
|
|
BDSI
9
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $4.37M | 3.83% |
517,662
-177,300
| -26% | -$1.43M |
|
|
10
Lesaka Technologies
LSAK
$391M
| $3.8M | 3.33% |
381,490
-324,976
| -46% | -$3.03M |
|
11
Pure Cycle
PCYO
$275M
| $3.73M | 3.26% |
616,000
+43,000
| +8% | +$270K |
|
12
Talphera
TLPH
$63.8M
| $2.99M | 2.62% |
12,449
-4,020
| -24% | -$953K |
|
|
PKT
13
DELISTED
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
| $2.95M | 2.58% |
283,690
+31,600
| +13% | +$373K |
|
14
Ubiquiti
UI
$35.9B
| $2.88M | 2.52% |
63,363
+20,900
| +49% | +$979K |
|
|
15
Accuray
ARAY
$31.3M
| $2.48M | 2.17% |
258,300
-271,200
| -51% | -$2.56M |
|
|
SANW
16
DELISTED
S&W Seed Co
SANW
| $2.34M | 2.05% |
16,624
+12,883
| +344% | +$1.65M |
|
|
SHOR
17
DELISTED
ShoreTel, Inc.
SHOR
| $2.1M | 1.83% |
+243,828
| New | +$2.1M |
|
18
Axogen
AXGN
$2.78B
| $1.68M | 1.47% |
550,607
-81,000
| -13% | -$323K |
|
|
ENVI
19
DELISTED
ENVIVIO INC COM STK (DE)
ENVI
| $1.67M | 1.47% |
542,622
+76,600
| +16% | +$272K |
|
|
P
20
DELISTED
Pandora Media Inc
P
| $1.65M | 1.44% |
54,400
-20,800
| -28% | -$720K |
|
|
NES
21
DELISTED
NUVERRA ENVIRONMENTAL INC NEW COM STK (DE)
NES
| $1.57M | 1.38% |
+77,400
| New | +$1.24M |
|
|
CUTR
22
DELISTED
Cutera, Inc.
CUTR
| $1.56M | 1.37% |
139,689
-14,400
| -9% | -$147K |
|
|
CSII
23
DELISTED
Cardiovascular Systems, Inc.
CSII
| $1.48M | 1.3% |
46,641
-10,300
| -18% | -$340K |
|
|
ENT
24
DELISTED
Global Eagle Entertainment Inc.
ENT
| $1.45M | 1.27% |
3,672
-200
| -5% | -$82.2K |
|
|
DRTX
25
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
| $1.42M | 1.25% |
+105,500
| New | +$1.38M |
|
Similar funds
SFM
IACGFA
LS
NGPI
AP
GRP
NVPV
AC
Sophrosyne Capital's Q1 2014 Portfolio in Review
As of Q1 2014, Sophrosyne Capital held 94 positions worth $114M, up 0.01% from $114M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Sophrosyne Capital withdrew a net $8.9M in Q1 2014, closing 16 positions and reducing 28 holdings. Its most notable exit was Calix, an estimated $6.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 55% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Sophrosyne Capital opened a new position in Benefytt Technologies, Inc. Class A Common Stock worth $4.65M.
- Sophrosyne Capital's largest Q1 2014 buy was Benefytt Technologies, Inc. Class A Common Stock: 449,845 shares worth $4.65M.
- Sophrosyne Capital added most to Syngenta Ag in Q1 2014, an estimated $5.86M increase.
- Sophrosyne Capital's biggest Q1 2014 reduction was Lesaka Technologies, cutting an estimated $3.03M.
- Sophrosyne Capital fully exited Calix in Q1 2014, selling an estimated $6.16M.
- Sophrosyne Capital's ten largest holdings make up 53% of its $114M portfolio in Q1 2014.
- Sophrosyne Capital opened 29 new positions and closed 16 in Q1 2014.
- Sophrosyne Capital's portfolio value rose 0.01% quarter-over-quarter to $114M.
Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.